<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680156</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-223</org_study_id>
    <nct_id>NCT04680156</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)</brief_title>
  <official_title>An Observational, Double-blind (Sponsor Open), Long-term Study to Evaluate the Safety and Durability (Efficacy) of Response to EN3835 Compared to Placebo in the Treatment of Adhesive Capsulitis of the Shoulder (Frozen Shoulder)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term follow-up study to evaluate the safety and durability (efficacy) of&#xD;
      response to EN3835 compared to placebo in participants who were treated in EN3835-210 or the&#xD;
      pivotal Phase 3 parent studies for the treatment of AC of the shoulder (frozen shoulder).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ASES composite score in affected shoulder</measure>
    <time_frame>Days 180, 270, and 360</time_frame>
    <description>The change from Day 95/end of study (EOS) in the parent studies in the adapted American Shoulder and Elbow Society (ASES) composite score for the affected shoulder</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">646</enrollment>
  <condition>Adhesive Capsulitis</condition>
  <condition>Frozen Shoulder</condition>
  <arm_group>
    <arm_group_label>EN3835</arm_group_label>
    <description>Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies</intervention_name>
    <description>No treatment to be administered - Observational only</description>
    <arm_group_label>EN3835</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All participants that have completed the EN3835-210 study or the pivotal Phase 3 studies in&#xD;
        which they were enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have been enrolled and completed the EN3835-210 or pivotal Phase 3 parent studies (for&#xD;
             Study EN3835-223 eligibility, completed participants are those who were assessed for&#xD;
             safety and obtained ASES scores at Day 95/EOS Visit; does not include early terminated&#xD;
             participants).&#xD;
&#xD;
          2. Be willing not to use pain medications for the duration of the study period and for 2&#xD;
             weeks prior to the Day 180 visit. Pain medications include but are not limited to:&#xD;
             barbiturates, benzodiazepines, methadone, buprenorphine, opioids (e.g., codeine,&#xD;
             heroin, hydrocodone, hydromorphone, morphine, oxycodone), and cannabis.&#xD;
&#xD;
             Note: NSAIDs (ibuprofen, etc.) are allowed.&#xD;
&#xD;
          3. Be willing to undergo MRI of the affected shoulder as required by the protocol.&#xD;
&#xD;
          4. Be able to read, understand, and independently complete patient reported outcome&#xD;
             instruments in English.&#xD;
&#xD;
          5. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
          6. Be adequately informed and understand the nature and risks of the study and be able to&#xD;
             provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is from a vulnerable population, as defined by the US Code of Federal Regulations&#xD;
             (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations,&#xD;
             including but not limited to, employees (temporary, part-time, full time, etc.) or a&#xD;
             family member of the research staff conducting the study, or of the sponsor, or of the&#xD;
             contract research organization, or of the IRB/IEC.&#xD;
&#xD;
          2. Plans to receive (or received prior to Day 180) any invasive or minimally invasive&#xD;
             (ie, steroid injections, shoulder manipulation, surgery, etc.) procedures to the&#xD;
             affected shoulder during study participation.&#xD;
&#xD;
             Note: PT is allowed. Any PT received should be captured in the respective electronic&#xD;
             case report form (eCRF).&#xD;
&#xD;
          3. Has any contraindications for MRI (implant containing metal, internal metallic object,&#xD;
             permanent cosmetics/make-up/tattoos-with exemption of the area to be treated/reviewed,&#xD;
             claustrophobia, syncope, low blood pressure, epilepsy, asthma, anemia, or sickle cell&#xD;
             disease) as determined by the technologist, the radiologist, and/or investigator&#xD;
             performing imaging.&#xD;
&#xD;
          4. Has any other conditions that, in the investigator's opinion, might indicate the&#xD;
             participant to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Kang</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deanna Lutte</last_name>
    <phone>800-462-3636</phone>
    <email>clinicaltrials@endo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Davina Cupo</last_name>
    <phone>800-462-3636</phone>
    <email>clinicaltrials@endo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #16</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #9</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #25</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #8</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #7</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #14</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #11</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #2</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #19</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #4</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #26</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #20</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #21</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #24</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #23</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #10</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #13</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #12</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #5</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #6</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #17</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #27</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #22</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #15</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #18</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #3</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

